Cargando…

A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper

BACKGROUND: Haematopoietic stem cell transplantation (HSCT) has been tried in the last 15 years as a therapeutic option in patients with poor-prognosis autoimmune disease who do not respond to conventional treatments. Worldwide, more than 600 patients with multiple sclerosis (MS) have been treated w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saccardi, R, Freedman, MS, Sormani, MP, Atkins, H, Farge, D, Griffith, LM, Kraft, G, Mancardi, GL, Nash, R, Pasquini, M, Martin, R, Muraro, PA
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2012
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3389500/ https://www.ncbi.nlm.nih.gov/pubmed/22383228 http://dx.doi.org/10.1177/1352458512438454

Ejemplares similares

Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with ‘aggressive’ multiple sclerosis
por: Das, J, et al.
Publicado: (2021)

Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)
por: Sharrack, Basil, et al.
Publicado: (2019)

Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation
por: Snowden, J A, et al.
Publicado: (2012)

Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline
por: Bayas, Antonios, et al.
Publicado: (2023)

Autologous haematopoietic stem cell transplantation versus low‐dose immunosuppression in secondary–progressive multiple sclerosis
por: Mariottini, Alice, et al.
Publicado: (2022)

Rehabilitation Before and After Autologous Haematopoietic Stem Cell Transplantation (AHSCT) for Patients With Multiple Sclerosis (MS): Consensus Guidelines and Recommendations for Best Clinical Practice on Behalf of the Autoimmune Diseases Working Party, Nurses Group, and Patient Advocacy Committee of the European Society for Blood and Marrow Transplantation (EBMT)
por: Roberts, Fiona, et al.
Publicado: (2020)

Changes on chest HRCT in systemic sclerosis-related interstitial lung disease after autologous haematopoietic stem cell transplantation
por: Pugnet, Grégory, et al.
Publicado: (2022)

Autologous haematopoietic stem cell therapy for multiple sclerosis: a review for supportive care clinicians on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation
por: Ismail, Azza, et al.
Publicado: (2019)

Autologous haematopoietic stem cell transplantation for neurological diseases
por: Burman, Joachim, et al.
Publicado: (2018)

The impact of repeated autologous infusion of haematopoietic stem cells in patients with liver insufficiency
por: Zekri, Abdel-Rahman N., et al.
Publicado: (2015)

The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis
por: Willison, A. G., et al.
Publicado: (2022)

Inhibitory KIR–HLA receptor–ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma
por: Leung, W, et al.
Publicado: (2007)

Haematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis: Recent Advances
por: Mariottini, Alice, et al.
Publicado: (2023)

Second autologous haematopoietic stem cell transplantation in systemic sclerosis—a case report
por: van Rhijn-Brouwer, Femke C C, et al.
Publicado: (2019)

Autologous haematopoietic stem cell transplantation for refractory stiff-person syndrome: the UK experience
por: Kass-Iliyya, Lewis, et al.
Publicado: (2020)

Autologous Haematopoietic Stem Cell Transplantation and Systemic Sclerosis: Focus on Interstitial Lung Disease
por: Bagnato, Gianluca, et al.
Publicado: (2022)

Correction to: The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis
por: Willison, A. G., et al.
Publicado: (2022)

Autologous Haematopoietic Stem Cell Transplantation for Crohn’s Disease: A Retrospective Survey of Long-term Outcomes From the European Society for Blood and Marrow Transplantation
por: Brierley, Charlotte K, et al.
Publicado: (2018)

Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphoma?
por: Hackshaw, A, et al.
Publicado: (2004)

Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantation
por: Armenian, Saro H., et al.
Publicado: (2020)

PB2193: IS HYPERHYDRATION NECESSARY FOR HIGH DOSE MELPHALAN CONDITIONING REGIMEN IN AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION?
por: Mora Argumánez, M., et al.
Publicado: (2022)

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS
por: Nash, Richard A., et al.
Publicado: (2017)

Myeloablative autologous haematopoietic stem cell transplantation resets the B cell repertoire to a more naïve state in patients with systemic sclerosis
por: Adamska, Julia Z, et al.
Publicado: (2023)

Chronic inflammatory demyelinating polyradiculoneuropathy occurring after autologous haematopoietic stem cell transplantation for multiple sclerosis
por: Simonsen, Cecilia Smith, et al.
Publicado: (2016)

Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study
por: Zhukovsky, Christina, et al.
Publicado: (2021)

Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis
por: Mariottini, Alice, et al.
Publicado: (2022)

Autologous Stem Cell Transplantation for Aggressive Lymphomas
por: Visani, Giuseppe, et al.
Publicado: (2012)

Cerebrospinal fluid cytokines after autologous haematopoietic stem cell transplantation and intrathecal rituximab treatment for multiple sclerosis
por: Burman, Joachim, et al.
Publicado: (2023)

General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases (ADs): A position statement from the EBMT Autoimmune Diseases Working Party (ADWP), the EBMT Nurses Group, the EBMT Patient, Family and Donor Committee and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
por: Jessop, Helen, et al.
Publicado: (2019)

Age independently affects myelin integrity as detected by magnetization transfer magnetic resonance imaging in multiple sclerosis
por: Newbould, R.D., et al.
Publicado: (2014)

Long-Term Suppression of Circulating Proinflammatory Cytokines in Multiple Sclerosis Patients Following Autologous Haematopoietic Stem Cell Transplantation
por: Hendrawan, Kevin, et al.
Publicado: (2022)

Anti-thymocyte globulin exposure in patients with diffuse cutaneous systemic sclerosis undergoing autologous haematopoietic stem cell transplantation
por: Chiu, Yu-Hsiang, et al.
Publicado: (2023)

Fully Immunocompetent CD8+ T Lymphocytes Are Present in Autologous Haematopoietic Stem Cell Transplantation Recipients Despite an Ineffectual T-Helper Response
por: Bandera, Alessandra, et al.
Publicado: (2008)

Late recovery of renal failure after autologous haematopoietic stem cell transplantation for multiple myeloma: a report of two cases
por: Bigé, Naïke, et al.
Publicado: (2009)

Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: a Review of Current Literature and Future Directions for Transplant Haematologists and Oncologists
por: Das, Joyutpal, et al.
Publicado: (2019)

Supplementation with Oral Vitamin C Prior to and during Myeloablative Chemotherapy and Autologous Haematopoietic Stem Cell Transplantation: A Pilot Study
por: Carr, Anitra C., et al.
Publicado: (2022)

Recapitulative haematopoietic development of human pluripotent stem cells in the absence of exogenous haematopoietic cytokines
por: Philonenko, Elena S., et al.
Publicado: (2021)

MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis
por: Uccelli, Antonio, et al.
Publicado: (2019)

Editorial: Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases: Where do we stand? Volume II
por: Malmegrim, K. C. R., et al.
Publicado: (2022)

Haematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease
por: Slatter, M. A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t2v52q6lt3rra399pjgl28oprv